Abstract
Background: There is increasing evidence regarding the correlation between the risk of death from cardiovascular disease and low levels of HDL-cholesterol or high plasma concentrations of LDL-cholesterol, total cholesterol, and triglycerides. Gonadotropin releasing hormone (GhRH) analogues are widely used in assisted reproduction programs. Therefore, it seems important to evaluate possible changes in serum lipoprotein levels following treatment with these compounds.
Purpose: Our purpose was to assess possible lipoprotein changes following administration of the long-acting GnRH analogue,d-Trp6 luteinizing hormone-releasing hormone (LH-RH).
Design: Serum levels of cholesterol, HDL-cholesterol, LDL-cholesterol, and triglicerydes were determined before and after 6 weeks of treatment.
Results: No significant changes in either cholesterol or HDL-cholesterol, LDL-cholesterol, or triglicerydes following treatment withd-Trp6 LH-RH were demonstrated in the group of 25 patients investigated.
Conclusions: Short-term use ofd-Trp6 LH-RH is not associated with any significant change in plasma lipid levels. Further studies are still required with patients undergoing repeated treatment cycles, especially those who exhibit elevated pretreatment plasma lipid levels, to confirm the long-term safety of GnRH analogues with respect to lipid metabolism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thatcher SS: Analogs of gonadotropin-releasing hormone in assisted reproduction. Assist Reprod Rev 1991;1:116–131
Goldman GA, Tadir Y, Ovadia J, Fisch B: The impact of D-Trp6 LH-RH on carbohydrate metabolism. J Assist Reprod Genet 1993;10:78–81
Consensus Conference: Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080–2086
Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuos and graded? JAMA 1986;256:2823–2828
Castelli WP, Garrison RJ, Wilson PWF,et al.: Incidence of coronary heart diseases and lipoprotein cholesterol levels. JAMA 1986;256:2835–2838.
Levy RI, Breniske JF, Epstein SE,et al.: The influence of changes in lipid values induced by cholestiramine and diet on progression of coronary artery disease: Results of NHLBI Type II coronary intervention study. Circ Res 1984;69:325–337
Speroff L, Glass RH, Kase NG: Clinical Gynecologic Endocrinology and Infertility, 4th ed. Baltimore, Williams and Wilkins, 1989, pp. 142–145
Speroff T, Dawson N, Speroff L: Is postmenopausal estrogen use risky? Results from a methodologic review and information synthesis. Clin Res 1987;35:362A
Hart DM, Farish E, Fletcher DC, Howie C, Kitchener H: Ten years postmenopausal hormone replacement therapy-effect on lipoproteins. Maturitas 1984;5:271–276
Bush TL, Barrett-Conor E, Cown DK, Criqui MH, Wallace RB, Suchindran CM,et al.: Cardiovascular mortality and non-contraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circ Res 1987;75:1102–1109
Keys A, Sidanza F, Karvonen MJ, Taylor HL: Indices of relative weight and obesity. J Chron Dis 1972;25:329–343
The National Cholesterol Education Program, National Heart, Lung and Blood Institute: Report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36–39
Nicoll A, Miller NE, Lewis B: High density lipoprotein metabolism. Adv Lipid Res 1980;53–56
Rijpkema AHM, van der Sanden AA, Ruijs AHC: Effects of postmenopausal estrogen-progestogen replacement therapy on serum lipids and lipoproteins: A review. Maturitas 1990;12:259–285
Burkman RT: Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy. Fertil Steril 1988;49(5; Suppl 2):39S-50S
Burry KA, Patton PE, Illingworth DR: Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol. Am J Obstet Gynecol 1989;60:1454–1461
Fahraeus L, Larsson-Cohn U, Ljunberg S, Wallentin L: Profound alterations of the lipoprotein metabolism during danazol treatment in premenopausal women. Fertil Steril 1984;42:52–57
Lemay A, Brideau NA, Forest JC,et al.: Cholesterol fractions and apolipoproteins during endometriosis treatment by GnRH agonist implant or by danazol. Clin Endocrinol 1991;35:305–310
Luciano AA, Hauser KS, Chapter FK,et al.: Effects of danazol on plasma lipid and lipoprotein levels in healthy women and in women with endometriosis. Am J Obstet Gynecol 1983;145:422–426
Consensus Development Meeting: Metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am J Obstet Gynecol 1990;162:1335–1337
Skuby SO, Jespersen J: Metabolic aspects of oral contraceptives of relevance for cardiovascular disease. Adv Contracept 1990;6 (Suppl):7–13
Goldberg B, Robin D, Alexander AN,et al.: Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apo proteins A-1 and B. J Clin Endocrinol Metab 1985;60:203–207
Farish E, Fletcher CD, Barnes JF, Mack A,et al.: Reversible menopause induced by the GnRH analogue Buserelin: effects on lipoprotein metabolism. Acta Endocrinol 1992;127:123–126
Dlugi AM, Rufo S, D'Amico JF, Seibel MM: A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Fertil Steril 1988;49:913–916
Henzl MR, Corson SL, Moghissi K,et al.: Administration of nasal Nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med 1988;318:485–489
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goldman, G.A., Schoenfeld, A., Ovadia, J. et al. The impact ofd-Trp6 LH-RH on plasma lipid levels. J Assist Reprod Genet 13, 223–227 (1996). https://doi.org/10.1007/BF02065940
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02065940